Xenomics Inc.

Xenomics' Subsidiary TrovaGene Secures Italian Patent for NPM1 Testing for AML Patients
Wireless News; 12/28/2009; 535 words; ...Wireless News 12-28-2009 Xenomics' Subsidiary TrovaGene...PatientsType: NewsXenomics, Inc., a developer of transrenal...managing patients with AML. Xenomics holds exclusive rights...trials for new therapies. Xenomics Inc. is focused on the development...

Xenomics' Subsidiary TrovaGene Gets Italian Patent for NPM1 Testing for AML Patients.
Health & Beauty Close-Up; 12/20/2009; 740 words; Xenomics, Inc., a developer of transrenal molecular...NPM1 in managing patients with AML. Xenomics holds exclusive rights to the application...during clinical trials for new therapies. Xenomics Inc. is focused on the development of nucleic...

Xenomics' Preliminary Investigation Leads the Company to Believe Sequenom Willfully Manipulated its Down Syndrome Data in its Presentations.
Business Wire; 12/17/2009; 1186 words; NEW YORK -- Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular...seek further damages from this consequence. About Xenomics, Inc. and TrovaGene (TM), Inc. Xenomics Inc. is focused on the development of DNA and RNA...

Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology.
Cancer Weekly; 11/24/2009; 1199 words; Xenomics, Inc. (XNOM.PK), a developer of transrenal...urine-based HPV screening (see also Xenomics, Inc.). "The HPV patent will be a valuable...Carcinomas, Viral Research, Virology, Xenomics Inc. This article was prepared by Cancer...

PreMarketData.com Early Session Standouts For Tuesday Include PCLN, XNOM, DVAX.
M2 Presswire; 11/10/2009; 1484 words; ...Incorporated (NASDAQ: PCLN), Xenomics, Inc. (XNOM.PK), and Dynavax...it at www.PreMarketData.com Xenomics, Inc. (XNOM.PK) announced today...Papilloma Virus (HPV) DNA, based on Xenomics transrenal DNA technology. The...